GlassScriptPhysician profile
Lori Jane Jones
NPI 1760946495
$6,162.72
in general payments reported to CMS, 2019-2025
29 companies · $509 in 2025
The $509 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $1,054 · 2023: $1,538 · 2024: $1,792 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.53 |
| Education | $214.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $868.57 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $670.28 | 2023-2025 | |
| Lilly USA, LLC | $647.95 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $586.45 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $520.49 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $427.39 | 2023-2024 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $384.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $339.50 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.81 | 2021-2024 | Jardiance |
| Amgen INC. | $190.25 | 2022-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $149.20 | 2021-2023 | |
| Janssen Biotech, INC. | $133.90 | 2024-2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $126.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
| Philips North America LLC | $112.54 | 2024 | (Ak6) Vest Therapy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $90.29 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.42 | 2022 | |
| Exact Sciences Corporation | $70.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $57.30 | 2021-2023 | Austedo Xr |
| Amarin Pharma, INC. | $56.80 | 2022 | |
| Abbott Laboratories | $54.84 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Corcept Therapeutics | $53.84 | 2021-2023 | Korlym |
| Merck Sharp & Dohme LLC | $48.76 | 2022-2023 | Verquvo |
| Radius Health, INC. | $41.95 | 2024 | Tymlos |
| Mylan Specialty L.P. | $35.50 | 2021-2024 | Yupelri |
| Esperion Therapeutics, INC. | $21.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.30 | 2021 | |
| Seqirus USA INC | $16.34 | 2025 | Flucelvax, Fluad |
| Horizon Therapeutics Plc | $14.83 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.